Results 191 to 200 of about 25,109 (253)

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors. [PDF]

Signal Transduct Target Ther
Llorente S, Lamarca A, Tian TV.
europepmc   +1 more source

Neuregulin-induced HER3 activation drives migration in head and neck squamous cell carcinoma via HER2 and FAK signaling pathways. [PDF]

Cell Oncol (Dordr)
Lim EJ, Yoon YJ, Heo J, Kim S, Choi YH, Kim YH.   +5 more
europepmc   +1 more source

Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates. [PDF]

Oncoimmunology
Kepp O, Kroemer G.
europepmc   +1 more source

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. [PDF]

J Clin Oncol
Steuer CE, Hayashi H, Su WC, Nishio M, Johnson ML, Kim DW, Massarelli E, Felip E, Gold KA, Murakami H, Baik CS, Kim SW, Smit EF, Fujimura M, Fan PD, Truchon K, Su X, Sternberg DW, Jänne PA.   +18 more
europepmc   +1 more source

Gastrin-Releasing Peptide Receptors Stimulate MAPK-Mediated Growth of Lung Cancer Cells by Transactivating HER4 in a Neuregulin-1, MAP Kinase-Dependent Manner Requiring Activation of the ROS-System. [PDF]

Biology (Basel)
Moody TW, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT.   +4 more
europepmc   +1 more source

Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Trontzas IP, He M, Wurtz A, Robbins CJ, Robinson N, Bates K, Liu M, Aung TN, Scott L, Chan N, Burela S, Schillo J, Liebler DC, Hill S, Morrison RD, Vathiotis I, Syrigos KN, Goldberg SB, Politi K, Rimm DL.   +19 more
europepmc   +1 more source

Transcriptome Analysis Suggested Striking Transition Around the End of Epiboly in the Gene Regulatory Network Downstream of the Oct4-Type POU Gene in Zebrafish Embryos. [PDF]

Dev Growth Differ
Ikeda M, Kobayashi K, Nakayama-Sadakiyo Y, Sato Y, Tobita A, Saito M, Yamasu K.   +6 more
europepmc   +1 more source

Patritumab deruxtecan induces immunogenic cell death. [PDF]

Oncoimmunology
Forveille S, Zhao L, Sauvat A, Cerrato G, Leduc M, Doffe F, Pan Y, Liu P, Kroemer G, Kepp O.   +9 more
europepmc   +1 more source

Effectiveness of afatinib after long-term gefitinib treatment for <i>EGFR</i> L858R and S768I compound mutation-positive lung adenocarcinoma: A case report. [PDF]

Respir Med Case Rep
Dai-Shinozaki A, Sakakibara-Konishi J, Hatanaka KC, Wakabayashi K, Shinagawa N, Matsuno Y, Hatanaka Y, Konno S.   +7 more
europepmc   +1 more source

Emerging Targets in Non-Small Cell Lung Cancer. [PDF]

Lung Cancer (Auckl)
Wang J, Biglow L, Baumgart M.
europepmc   +1 more source